Description
Highlights of the 2019 annual meeting of the European Neuroendocrine Tumour Society (ENETS)
- You cannot add another "Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma" to your cart. View cart
Article: Highlights of the 2019 annual meeting of the European Neuroendocrine Tumour Society (ENETS)
€3.03
Reviews
There are no reviews yet.